GSK (GSK) Tops Q4 Earnings and Revenue Estimates

Company Performance - GSK reported quarterly earnings of $0.59 per share, exceeding the Zacks Consensus Estimate of $0.53 per share, but down from $0.72 per share a year ago, representing an earnings surprise of 11.32% [1] - The company posted revenues of $10.4 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.04%, compared to year-ago revenues of $10 billion [2] - Over the last four quarters, GSK has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Future Outlook - The sustainability of GSK's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - Current consensus EPS estimate for the coming quarter is $1.11 on revenues of $9.67 billion, and for the current fiscal year, it is $4.07 on revenues of $40.5 billion [7] - The estimate revisions trend for GSK is currently unfavorable, resulting in a Zacks Rank 5 (Strong Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which GSK belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]